학술논문
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
Document Type
Article
Author
Coppens, M.; Pipe, S.W.; Miesbach, W.; Astermark, J.; Recht, M.; van der Valk, P.; Ewenstein, B.; Galante, N.; Monahan, P.E.; Pinachyan, K.; Le Quellec, S.; Leebeek, F.W.G.; Castaman, G.; Crary, S.E.; Escobar, M.; Gomez, E.; Haley, K.M.; Hermans, C.R.J.R.; Kampmann, P.; Kazmi, R.; Key, N.S.; Klamroth, R.; Konkle, B.A.; Kruse-Jarres, R.; Lattimore, S.; Lemons, R.; Meijer, K.; O'Connell, N.; Quon, D.V.; Raheja, P.; Symington, E.; Verhamme, P.; Visweshwar, N.; von Drygalski, A.; Wang, M.; Wheeler, A.P.; White, S.; Young, G.
Source
In: The Lancet Haematology . (The Lancet Haematology, April 2024, 11(4):e265-e275)
Subject
Language
English
ISSN
23523026